Avadel Pharmaceuticals (AVDL) EBIT: 2009-2021
Historic EBIT for Avadel Pharmaceuticals (AVDL) over the last 12 years, with Dec 2021 value amounting to -$23.1 million.
- Avadel Pharmaceuticals' EBIT fell 62.24% to -$23.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$85.5 million, marking a year-over-year decrease of 1571.13%. This contributed to the annual value of -$85.5 million for FY2021, which is 1571.13% down from last year.
- According to the latest figures from Q4 2021, Avadel Pharmaceuticals' EBIT is -$23.1 million, which was up 9.85% from -$25.7 million recorded in Q3 2021.
- Over the past 5 years, Avadel Pharmaceuticals' EBIT peaked at $40.3 million during Q2 2020, and registered a low of -$75.4 million during Q4 2018.
- Moreover, its 3-year median value for EBIT was -$10.9 million (2019), whereas its average is -$8.7 million.
- As far as peak fluctuations go, Avadel Pharmaceuticals' EBIT slumped by 1,748.55% in 2018, and later spiked by 1,004.72% in 2020.
- Quarterly analysis of 5 years shows Avadel Pharmaceuticals' EBIT stood at -$4.1 million in 2017, then slumped by 1,748.55% to -$75.4 million in 2018, then skyrocketed by 90.26% to -$7.3 million in 2019, then slumped by 94.09% to -$14.3 million in 2020, then tumbled by 62.24% to -$23.1 million in 2021.
- Its last three reported values are -$23.1 million in Q4 2021, -$25.7 million for Q3 2021, and -$21.9 million during Q2 2021.